Heterogeneity of intermediate prognosis patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib.
Avishay Sella
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Novartis; Pfizer
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bayer; GlaxoSmithKline; Novartis; Pfizer
M. Dror Michaelson
Research Funding - Pfizer
Ewa M. Matczak
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Ronit Simantov
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Mariajose Lechuga
Disclosure not yet available
Xun Lin
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Robert A. Figlin
Consultant or Advisory Role - Pfizer